In a David-and-Goliath lawsuit kept under wraps for two years in arbitration, a tiny drug research company in Spain won its case against a U.S. pharmaceutical giant in February, clearing the way to begin manufacturing its new drug.
The arbitration stretched over five days as international experts debated the scientific procedures used to produce the drug. In the end, the methods used by the R&D company were fully vindicated. Within days, the big pharma company paid damages, thereby under the arbitration rules avoiding disclosure of its identity.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
